9071-8776 Quebec Inc. Acquires Further Interest in DIAGNOS Inc.
November 05 2020 - 4:31PM
In accordance with regulatory requirements, Diagnos Inc. (“DIAGNOS”
or “the Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader
in early detection of critical health issues through the use of its
FLAIRE platform based on Artificial Intelligence (AI) announces
that 9071-8776 Quebec Inc. (the “Acquiror”) has acquired 3,076,922
common shares (“Shares”) of the Corporation pursuant to an exercise
of 3,076,922 stock warrants at a price of $0.13 per share on
November 4, 2020, for a rounded consideration of $400,000. As a
result, the Acquiror’s percentage of the Shares of the Issuer, on
an undiluted basis, increased by 3.47%, directly and indirectly,
since the last Form 62-103F1 was filed.
Immediately before the acquisition of 3,076,922
Shares, the Acquiror held, directly and indirectly, 4,706,139, or
7.65%, of the outstanding Shares of the Corporation, on an
undiluted basis. Immediately after the acquisition of 3,076,922
Shares, the Acquiror holds, directly and indirectly, 7,783,061, or
12.04%, of the outstanding Shares of the Corporation, on an
undiluted basis. The acquisition of 3,076,922 Shares did not have
an impact on the number and percentage of the outstanding Shares of
the Corporation on a partially diluted basis.
The Acquiror acquired the Shares of the
Corporation for investment purposes only. The Acquiror intends to
review, on a continuous basis, various factors related to its
investment, including, but not limited to, the price and
availability of the securities of the Corporation, subsequent
developments affecting the Corporation or its business, and the
general market and economic conditions. Based upon these and other
factors, the Acquiror may decide to purchase additional securities
of the Corporation or may decide to sell all or part of its
investments.
The Corporation is also reporting that on
October 23, 2020, the Acquiror disposed 2,000,000 Shares of the
Corporation at a price of $0.50 per Share. Immediately before the
disposal, the Acquiror held, directly and indirectly, 11,352,561,
or 17.29%, of the outstanding Shares of the Corporation, on a
partially diluted basis. Immediately after the disposal, the
Acquiror held, directly and indirectly, 9,402,561, or 14.32%, of
the outstanding Shares of the Corporation, on a partially diluted
basis.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian
corporation with a mission of early detection of critical health
issues through the use of its Artificial Intelligence (“AI”) tool
CARA (Computer Assisted Retina Analysis). CARA is a
tele-ophthalmology platform that integrates with existing equipment
(hardware and software) and processes at the point of care. CARA’s
Artificial Intelligence image enhancement algorithms make standard
retinal images sharper, clearer and easier to read. CARA is
accessible securely over the internet, and is compatible with all
recognized image formats and brands of fundus cameras, and is EMR
compatible. CARA is a cost-effective tool for screening large
numbers of patients in real-time. CARA complies with local
regulations, is FDA cleared for commercialization in the United
States of America, is Health Canada licensed for commercialization
in Canada and is CE marking compliant in Europe.
Additional information is available at
www.diagnos.com and www.sedar.com.
For further information, please contact:
Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca
Diagnos (TSXV:ADK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Apr 2023 to Apr 2024